Latest News and Events
Filter by
Selections
June 9, 2016
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521
Read MoreJune 3, 2016
Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
Read MoreMay 6, 2016
Arrowhead Pharmaceuticals’ Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration
Read MoreApril 28, 2016
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521
Read MoreApril 18, 2016